Access to Innovation / Newsletters / Home

Access to Innovation | View Recent

Date	Name
April 21, 2008	Underlying chronic conditions significantly increase hospital spending in Canada
December 14, 2007	Treatment of rare disorders: U.S and Europe enact legislation to encourage innovation and access while Canada lags behind.
December 05, 2007	Generic drug savings? Canadian consumers pay significantly more for generic drugs than Americans.
July 05, 2007	Last year, prescription drugs were the smallest component of government health care spending growth in Canada
May 22, 2007	Canada appears to lag behind U.S. in progress in the war on cancer
May 21, 2007	Canada accuse un certain retard par rapport aux États-Unis dans le combat contre le cancer
October 04, 2006	Canada’s National Pharmaceutical Strategy: Improving access to medicines or containing costs by limiting patient/physician treatment choices?
September 11, 2006	Growing numbers of employers use care management strategies to combat chronic disease risk factors and contain health benefit costs
August 22, 2006	The prevalence of chronic conditions is much higher among obese Canadians.
February 27, 2006	Focusing on improving health outcomes instead of decreasing access to testing and treatments will do more to contain health spending growth.
December 11, 2005	Despite misleading claims that drugs accounted for most of Canadian health care spending growth, institutional care continues to drive Canadian health spending
November 10, 2005	Community-based asthma education programs help British Columbia cut asthma hospitalizations in half.
October 25, 2005	The case for pharmacist involvement in patient health management.
August 01, 2005	Canadians with asthma have higher health service utilization
June 12, 2005	Covering Treatments for Rare Disorders will have Little Impact on Drug Plan Costs
April 26, 2005	Obesity may overtake smoking as the leading actual cause of death.
April 05, 2005	In 2004 institutional care drove provincial health spending growth.
March 31, 2005	Despite significant increases in drug utilization, hospitalizations for adverse effects have declined in Canada.
February 15, 2005	PHARMACEUTICAL POLICY CONSULTATION PAPER
February 01, 2005	After first year of operation Common Drug Review rejects 60% of drugs reviewed.
January 18, 2005	Conflicting Trends in 2004 Health Spending May Signal Higher Future Health Spending Growth.
November 08, 2004	Shift in Ontario health service utilization between 1996 and 2001 produces significant savings in avoided hospital costs.
October 11, 2004	Ontario initiative to restrict drug benefits is likely to increase overall health costs by negating the potential to improve health outcomes.
September 26, 2004	Providing access to new medicines can help manage the costs associated with the huge growth in the number of Canadians with chronic conditions.
September 15, 2004	Special Report: First Ministers Meeting, September 13-15: Timely access to care emerges as a national priority.
July 13, 2004	Consumers and patients must have an integral role in health decision making in Canada.
May 24, 2004	R&D in Canada lags behind other major industrialized countries, except Italy
May 03, 2004	Canadians with lower incomes are more likely to have poorer health outcomes.
December 08, 2003	Effective treatments can improve the quality of life for those living with asthma and allergies and can save health resources.
September 28, 2003	Slower drug approval times do not improve patient safety.
September 04, 2003	National health survey reveals that Canadians with arthritis/rheumatism have much higher health service utilization.
July 05, 2003	Recognizing the negative impacts of pricing and reimbursement delays, Europe pursues measures to boost pharmaceutical innovation for the benefit of patients.
June 24, 2003	Canadians patients wait longer than patients in other countries for access to new drugs because of lengthy approval times.
May 10, 2003	Increased spending on prescription drugs can help to contain other health costs.
April 08, 2003	Formulary restrictions on antidepressant medications undermine the effective management of depression and related disorders.
March 09, 2003	Innovation versus Imitation: study concludes that patents are significantly more important in the area of pharmaceuticals than in other industries.
February 23, 2003	Mail-order internet pharmacies in Canada cannot meet the needs of American consumers and may cause shortages for Canadian patients.
February 14, 2003	Incremental advances in pharmaceutical innovation help lower drug costs while improving the quality of care.
February 14, 2003	Incremental advances in pharmaceuticals provide the elderly with more treatment options and improved health outcomes.
January 10, 2003	Policies that support incremental as well as breakthrough innovation are essential to improving clinical and economic outcomes in the treatment of diabetes.
December 08, 2002	Recent study shows that long term disability from arthritis in Canada costs $3.4 billion annually in lost productivity.
November 28, 2002	Romanow Commission Special Report
November 18, 2002	Latest data confirms Institutional care as primary cost driver of provincial health spending.
September 30, 2002	Few new medicines are available to those who depend on provincial drug benefit programs.
September 08, 2002	Managing the growth of chronic conditions will challenge Canadian health care delivery.
August 11, 2002	Advertising of prescription drugs can help improve the health of Canadians and save health resources.
July 23, 2002	Shifting costs from hospitals and other institutions to outpatient services and prescription drugs is good news for Canada's health care system.
June 20, 2002	Prescription drugs account for a small proportion of provincial health spending growth
May 16, 2002	Aggressive Management & Monitoring of Diabetes Improves Health & Saves Health Care Resources.
April 28, 2002	Incremental improvements in ulcer/reflux disease drug therapies save hundreds of millions annually, in avoided hospital costs.
March 20, 2002	Increased spending on prescription drugs can lead to reductions in other health costs.